Sarcoidosis and the rheumatologist

Abstract

Many questions remain to be answered. More studies looking at the reliability of certain serological and radiological biomarkers are needed. Issues concerning the safety of the use of biological response modifiers in inducing sarcoidosis need further study.

A Nationwide Survey of Pulmonary Sarcoidosis Clinics in the United States

“…As sarcoidosis is a systemic disease that can affect any organ system (pulmonary, skin, and eye among the most common] [9], it is somewhat intuitive that a multispecialty clinic model could improve patient experience and outcomes. As supported by our study, rheumatology clearly plays an important role in the multidisciplinary management of sarcoidosis [10]. The most common other subspecialties other than pulmonary that are involved in the currently existing multispecialty clinics include those associated with the more common disease manifestations (dermatology and ophthalmology) and the manifestations that can be life threatening (cardiology and neurology) [11].…”

Parotid gland involvement as initial symptom in a patient with sarcoidosis

“…[6] Bu bildiride parotis bezi büyümesi ile baflvuran ve yap›lan tetkikler sonucu Löf-gren sendromu tan›s› alan ve onam formu al›nan bir olgu rapor ettik.…”

Romatolog gözüyle sarkoidoz

“…Semptomatik sarkoid miyozit %1-5 s›kl›¤›nda bildirilmifltir [1] ve akut granülomatöz miyozit, kronik miyopati ve nodüler miyopati olmak üzere üç formda ortaya ç›kar. [25] En s›k görülen form kronik miyopati olup, özellikle alt ekstremite proksimal kas gruplar›nda sinsi seyirli güçsüzlük, miyalji, derin tendon reflekslerinde azalma ve zay›flama ile kendini gösterir. [1,26] Kas enzimleri normal veya hafif yüksektir; elektromiyografide (EMG) miyopati bulgular› saptan›r.…”